Clinical Trial News and Research

RSS

Racial disparities in quality of communication between physicians and patients

A study comparing how physicians discuss clinical trials during clinical interactions with black patients versus white patients further confirms racial disparities in the quality of communication between physicians and patients.

30 Oct 2012

Immigration status, language of caregivers appear to impact care of Hispanic children with cancer

Language barriers and the immigration status of caregivers appear to impact the care of Hispanic children with cancer and affect the experience of the families within the medical system, according to data presented at the Fifth AACR Conference on The Science of Cancer Health Disparities, held here Oct. 27-30, 2012.

30 Oct 2012

Researchers decode software instructions that drive 3 different forms of acute lymphoblastic leukemia

30 Oct 2012

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2013.

30 Oct 2012

TTP488 slows cognitive decline in patients with mild to moderate Alzheimer's

A novel, orally administered drug candidate, TTP488, has demonstrated clinical evidence of slowing of cognitive decline over 18 months of therapy in patients with mild to moderate Alzheimer's disease.

30 Oct 2012

Scientists decode epigenetic programming of three virulent forms of acute lymphoblastic leukemia

A team of national and international researchers, led by Weill Cornell Medical College scientists, have decoded the key "software" instructions that drive three of the most virulent forms of acute lymphoblastic leukemia (ALL). They discovered ALL's "software" is encoded with epigenetic marks, chemical modifications of DNA and surrounding proteins, allowing the research team to identify new potential biomarkers and therapeutic targets.

29 Oct 2012

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.

29 Oct 2012

Neuros Medical honored as most promising startup

Neuros Medical, Inc., a medical device company, was presented the 2012 Gold Electrode Award for Most Promising Startup at the Neurotech Leaders Forum conference in San Francisco. The award is given by Neurotech Reports, and highlights a company in the neuromodulation industry that holds the most promise.

29 Oct 2012

Cellectis announces successful programming of immune system cells to kill cancer cells

Cellectis, the genome engineering specialist, has announced successfully programming cells from the immune system (T cells) to kill cancer cells. This technological breakthrough was revealed for the first time ever on Saturday, October 27th at the congress of the ESGCT (European Society of Gene & Cell Therapy) in Versailles, outside Paris.

29 Oct 2012

New HIV test for babies differs from conventional test, delivers diagnosis in less than an hour

Today, mothers in Africa sometimes walk more than 10 miles to a clinic only to learn that conventional HIV test results for their babies are not available yet.

29 Oct 2012

NewYork-Presbyterian/Columbia participates in Symplicity system trial for hypertension

Patients with hypertension whose blood pressure cannot be brought down to safe levels despite taking three or more medications may have some relief coming their way. An innovative, first-of-its-kind clinical trial for a device representing a dramatic shift in treatment approaches for the toughest-to-treat patients is currently being conducted at NewYork-Presbyterian Hospital.

From Medtronic 26 Oct 2012

PFO closure with investigational device may prevent cryptogenic ischemic stroke

A clinical trial indicates that using an investigational medical device to close a PFO, or "hole in the heart," may be superior to medical management alone in the prevention of a repeated stroke.

26 Oct 2012

Durata completes target enrollment in dalbavancin Phase 3 trial for ABSSSI

Durata Therapeutics today announced that it has completed its target enrollment for DISCOVER 2 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response"), the second global, Phase 3 clinical trial of Durata's lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria.

26 Oct 2012

Simple video game can help children with serious anger problems

Children with serious anger problems can be helped by a simple video game that hones their ability to regulate their emotions, finds a pilot study at Boston Children's Hospital. Results were published online October 24 in the journal Adolescent Psychiatry.

25 Oct 2012

Kessler Foundation expert to study effects of prism adaptation therapy for spatial neglect

A.M. Barrett, MD, of Kessler Foundation received a grant totaling $595,756 to study the effects of prism adaptation therapy for spatial neglect in survivors of right-sided stroke.

25 Oct 2012

Mesh-covered stent improves restoration of blood flow after PCI in heart attack patients

A clinical trial found that the use of a next generation, micronet, mesh-covered stent demonstrated improved restoration of blood flow to heart tissue, compared to the use of either bare-metal or drug-eluting stents in heart attack patients undergoing angioplasty.

25 Oct 2012

BioLineRx intends to conduct interim analysis of BL-1020 Phase II/III trial for schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that it intends to conduct an interim analysis of the Phase II/III CLARITY trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

25 Oct 2012

Scientists create new compounds that could slow progression of Parkinson's

In an early-stage breakthrough, a team of Northwestern University scientists has developed a new family of compounds that could slow the progression of Parkinson's disease.

25 Oct 2012

Ophthotech announces data from Fovista Phase 2b trial on wet AMD

Ophthotech Corporation today announced that data from a large, prospective, randomized, controlled Phase 2b clinical trial of Ophthotech's Fovista anti-PDGF therapy (1.5 mg) in patients with neovascular age-related macular degeneration (wet AMD) will be presented during Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO) on Sat., Nov. 10, 2012 at 9:15 a.m.

25 Oct 2012

Study evaluates frequency and features of very large treatment effects of medical interventions

In an examination of the characteristics of studies that yield large treatment effects from medical interventions, these studies were more likely to be smaller in size, often with limited evidence, and when additional trials were performed, the effect sizes became typically much smaller, according to a study in the October 24/31 issue of JAMA.

25 Oct 2012

Clinical Trial News and Research

Racial disparities in quality of communication between physicians and patients

Immigration status, language of caregivers appear to impact care of Hispanic children with cancer

Researchers decode software instructions that drive 3 different forms of acute lymphoblastic leukemia

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

TTP488 slows cognitive decline in patients with mild to moderate Alzheimer's

Scientists decode epigenetic programming of three virulent forms of acute lymphoblastic leukemia

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

Neuros Medical honored as most promising startup

Cellectis announces successful programming of immune system cells to kill cancer cells

New HIV test for babies differs from conventional test, delivers diagnosis in less than an hour

NewYork-Presbyterian/Columbia participates in Symplicity system trial for hypertension

PFO closure with investigational device may prevent cryptogenic ischemic stroke

Durata completes target enrollment in dalbavancin Phase 3 trial for ABSSSI

Simple video game can help children with serious anger problems

Kessler Foundation expert to study effects of prism adaptation therapy for spatial neglect

Mesh-covered stent improves restoration of blood flow after PCI in heart attack patients

BioLineRx intends to conduct interim analysis of BL-1020 Phase II/III trial for schizophrenia

Scientists create new compounds that could slow progression of Parkinson's

Ophthotech announces data from Fovista Phase 2b trial on wet AMD

Study evaluates frequency and features of very large treatment effects of medical interventions

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer